7 results
The primary objective of this study is to determine the response rate of electrochemotherapy in head and neck cancer. Secondary objectives are to monitor local and systemic side effects and adverse events and to determine quality of life before and…
Primary Objectives:- To determine the clinical efficacy of IRE ablation of small renal masses (* 4cm), assessed by calculating recurrence and residual disease at follow-up, measured through the (non-)presence of tumour enhancement on cross-sectional…
Primary Objectives:- To determine the efficacy of IRE ablation of renal masses, measured by histopathologic examination of the targeted tumour.- To determine the safety of IRE ablation of small renal masses, by evaluating device and procedural…
This study is looking at how safe the combination of the experimental drugs dostarlimab, belrestotug and GSK6097608 is in patients with previously untreated, advanced or metastatic non-small cell lung cancer. And how well the combination works. We…
DOSE EXPLORATION:Primary:To determine the safety and tolerability of GSK2857916 in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each sub-study combination treatment.Secondary:…
Primary objective:To estimate the efficacy of dostarlimab in participants with Stage II/III (locally advanced) dMMR/MSI-H rectal cancer that has not been previously treatedSecondary Objectives:- To further estimate the efficacy of dostarlimab in…
Primary (PART 1A ONLY):Dose escalation: To determine the safety, tolerability, and the recommended phase 2 dose (RP2D) of GSK3745417 alone administered intravenously to participants with selected advanced/recurrent solid tumors.Secondary: (PART 1A…